Paul Tudor Jones Cerevel Therapeutics Holdings, Inc. Transaction History

Tudor Investment Corp Et Al

  • $25.1 Billion
  • Q4 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024
BUY
$38.96 - $42.75 $3.3 Million - $3.63 Million
84,806 Added 203.22%
126,538 $5.17 Million
Q1 2024

May 15, 2024
BUY
$40.88 - $43.27 $1.71 Million - $1.81 Million
41,732 New
41,732 $1.76 Million
Q3 2023

Nov 15, 2023
BUY
$20.26 - $31.91 $1.61 Million - $2.54 Million
79,450 New
79,450 $1.73 Million

Others Institutions Holding CERE

# of Institutions
7
Shares Held
5.01M
Call Options Held
3.3K
Put Options Held
0
View Full List

About Cerevel Therapeutics Holdings, Inc.

CERE Quotes by TradingView
  • Ticker CERE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 155,752,000
  • Description
  • Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...
More about CERE
Track Paul Tudor Jones's Portfolio

Track Paul Tudor Jones Portfolio

Follow Paul Tudor Jones (Tudor Investment Corp Et Al) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

News

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email